论文部分内容阅读
A new compound 3-(2-(3,5-diphenyl-4,5-dihydropyrazol-1-yl)thiazol-4-yl)-2Hchromen-2-one was synthesized by cyclocondensation of 3,5-diphenyl-4,5-dihydropyrazole-1-carbothioamide with 3-(2-bromoacetyl)-2H-chromen-2-one in ethanol at reflux for 2hrs. The compound was characterized by IR, 1H-NMR, 13C-NMR and single-crystal X-ray diffraction analysis. The newly synthesized compound(C27H19N3O2S) crystallizes in the triclinic system, space group P1 with a = 5.2476(6), b = 18.289(2), c = 23.115(3) , α = 93.546(7), β = 94.715(6), γ = 92.347(7)°, V = 2204.3(4)3, Z = 4, Mr = 449.51, crystal size = 0.38 mm × 0.22 mm × 0.16 mm,(I > 2σ(I)) = 35317, 9736, 3785, Rint = 0.081,(Δρ)max = 0.19 and(Δρ)min = –0.24 e·-3. DNA interaction studies revealed that the target compound strongly interacts with DNA through an intercalation binding mode and the binding constant of the compound is 7.45 × 104 M-1.
A new compound 3- (2- (3,5-diphenyl-4,5-dihydropyrazol-1-yl) thiazol-4-yl) -2Hchromen-2-one was used by cyclocondensation of 3,5-diphenyl- 5-dihydropyrazole-1 -carothioamide with 3- (2-bromoacetyl) -2H-chromen-2-one in ethanol at reflux for 2 hrs. The compound was characterized by IR, 1H-NMR, 13C-NMR and single- ray diffraction analysis of the newly synthesized compound (C27H19N3O2S) crystallizes in the triclinic system with space group P1 with a = 5.2476 (6), b = 18.289 (2), c = 23.115 (I> 2σ (I> 94.715), γ = 92.347 (7) °, V = 2204.3 (4) 3, Z = 4, Mr = 449.51, crystal size = 0.38 mm × 0.22 mm × 0.16 mm ) = 35317, 9736, 3785, Rint = 0.081, (Δρ) max = 0.19 and (Δρ) min = -0.24 e · -3. DNA interaction studies revealed that the target compound strongly interacts with DNA through an intercalation binding mode and the binding constant of the compound is 7.45 × 104 M-1.